Moors & Cabot, Inc. Intellia Therapeutics, Inc. Transaction History

Moors & Cabot, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	BUY	$33.21 - $62.69 $92,988 - $175,532	2,800 New	2,800 $97,000
Q2 2022 Aug 08, 2022	SELL	$38.49 - $76.21 $107,772 - $213,387	-2,800 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $80,608 - $110,688	800 Added 40.0%	2,800 $331,000
Q3 2021 Dec 08, 2021	BUY	$132.37 - $176.78 $52,948 - $70,712	400 Added 25.0%	2,000 $267,000
Q3 2021 Nov 05, 2021	SELL	$132.37 - $176.78 $52,948 - $70,712	-400 Reduced 20.0%	1,600 $223,000
Q2 2021 Aug 10, 2021	BUY	$60.88 - $161.91 $121,760 - $323,820	2,000 New	2,000 $324,000
Q2 2019 Jul 18, 2019	SELL	$13.88 - $18.41 $146,434 - $194,225	-10,550 Closed	0 $0
Q1 2019 May 06, 2019	SELL	$12.79 - $17.62 $134,934 - $185,891	-10,550 Reduced 50.0%	10,550 $184,000
Q1 2019 May 01, 2019	BUY	$12.79 - $17.62 $269,869 - $371,782	21,100 New	21,100 $368,000
Q4 2018 Feb 13, 2019	SELL	$11.39 - $27.13 $110,483 - $263,161	-9,700 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$25.78 - $32.6 $12,890 - $16,300	-500 Reduced 4.9%	9,700 $275,000
Q2 2018 Aug 14, 2018	BUY	$20.02 - $30.79 $204,204 - $314,058	10,200 New	10,200 $279,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.